labetalol has been researched along with Birth Weight in 13 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 9.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 7.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 7.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 7.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "This was a nested cohort study of women with chronic hypertension and a singleton pregnancy recruited to the PANDA (Pregnancy And chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment) study at one of three UK maternity units." | 5.30 | Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study. ( Chappell, LC; Cruickshank, JK; Khalil, A; Mills, C; Myers, JE; Nelson-Piercy, C; Seed, PT; Watt-Coote, I; Webster, LM, 2019) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 5.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 5.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 3.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 3.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 3.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "Neonatal hypertension is increasingly recognized as dramatic improvements in neonatal intensive care, advancements in our understanding of neonatal physiology, and implementation of new therapies have led to improved survival of premature infants." | 2.61 | Neonatal hypertension: cases, causes, and clinical approach. ( Flynn, JT; Starr, MC, 2019) |
| "To assess the influence of intrauterine growth retardation on heart rate (HR) and HR variability during sleep, we performed polygraphic recordings in 10 small-for-gestational age (SGA) and 16 appropriate-for-gestational age (AGA) newborns." | 1.29 | Heart rate and heart rate variability during sleep in small-for-gestational age newborns. ( Clairambault, J; Curzi-Dascalova, L; Eiselt, M; Kauffmann, F; Médigue, C; Peirano, P; Spassov, L, 1994) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 1.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Dublin, S | 1 |
| Idu, A | 1 |
| Avalos, LA | 1 |
| Cheetham, TC | 1 |
| Easterling, TR | 1 |
| Chen, L | 1 |
| Holt, VL | 1 |
| Nance, N | 1 |
| Bider-Canfield, Z | 1 |
| Neugebauer, RS | 1 |
| Reynolds, K | 1 |
| Badon, SE | 1 |
| Shortreed, SM | 1 |
| Magee, LA | 1 |
| Singer, J | 1 |
| Lee, T | 1 |
| McManus, RJ | 1 |
| Lay-Flurrie, S | 1 |
| Rey, E | 1 |
| Chappell, LC | 2 |
| Myers, J | 1 |
| Logan, AG | 1 |
| von Dadelszen, P | 1 |
| Fitton, CA | 1 |
| Steiner, MFC | 1 |
| Aucott, L | 1 |
| Pell, JP | 1 |
| Mackay, DF | 1 |
| Fleming, M | 1 |
| McLay, JS | 1 |
| Webster, LM | 1 |
| Myers, JE | 1 |
| Nelson-Piercy, C | 1 |
| Mills, C | 1 |
| Watt-Coote, I | 1 |
| Khalil, A | 1 |
| Seed, PT | 1 |
| Cruickshank, JK | 1 |
| Starr, MC | 1 |
| Flynn, JT | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Lee, MS | 1 |
| Lardoux, H | 1 |
| Gerard, J | 1 |
| Blazquez, G | 1 |
| Flouvat, B | 1 |
| Dubois, D | 1 |
| Petitcolas, J | 1 |
| Temperville, B | 1 |
| Klepper, A | 1 |
| Leboullenger, P | 1 |
| Spassov, L | 1 |
| Curzi-Dascalova, L | 1 |
| Clairambault, J | 1 |
| Kauffmann, F | 1 |
| Eiselt, M | 1 |
| Médigue, C | 1 |
| Peirano, P | 1 |
| Saotome, T | 1 |
| Minoura, S | 1 |
| Terashi, K | 1 |
| Sato, T | 1 |
| Echizen, H | 1 |
| Ishizaki, T | 1 |
| Laml, T | 1 |
| Hartmann, BW | 1 |
| Preyer, O | 1 |
| Ruecklinger, E | 1 |
| Soeregi, G | 1 |
| Wagenbichler, P | 1 |
| Michael, CA | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The CHIPS Trial (Control of Hypertension In Pregnancy Study)[NCT01192412] | 987 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Use of Meditation as a Complementary Therapy in the Treatment of Gestational Hypertension[NCT03873194] | 47 participants (Actual) | Interventional | 2019-04-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pregnancy loss or NICU admission for greater than 48 hours, as recorded in the maternal and infant medical records immediately following the birth (or pregnancy loss), and then again after the mothers' and infants' discharge home. Supplemental information, about potential post-discharge maternal or neonatal morbidities in the 6 weeks following birth for the mother, or 28 days of life for the baby, will be obtained by contacting women at 6 weeks postpartum and/or from medical records. (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 155 |
| 'Tight' Control. | 150 |
"Serious maternal complications measured up to 6 weeks postpartum. Death or one or more life-threatening maternal complications:~Adverse neurological complications (stroke, eclampsia, and/or blindness), and/or~End-organ failure (uncontrolled hypertension, inotropic support, pulmonary oedema, respiratory failure, myocardial ischaemia/infarction, renal failure, coagulopathy, and/or transfusion)" (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 18 |
| 'Tight' Control. | 10 |
2 reviews available for labetalol and Birth Weight
| Article | Year |
|---|---|
In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review.
Topics: Antihypertensive Agents; Attention Deficit Disorder with Hyperactivity; Birth Weight; Child; Child H | 2017 |
Neonatal hypertension: cases, causes, and clinical approach.
Topics: Administration, Intravenous; Antihypertensive Agents; Birth Weight; Blood Pressure; Blood Pressure D | 2019 |
3 trials available for labetalol and Birth Weight
| Article | Year |
|---|---|
Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension; Hypertension, Pregnancy- | 2020 |
Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study.
Topics: Adult; Antihypertensive Agents; Birth Weight; Black People; Blood Pressure; Chronic Disease; Cohort | 2019 |
Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy.
Topics: Adolescent; Adult; Birth Weight; Clinical Trials as Topic; Delivery, Obstetric; Diazoxide; Female; H | 1986 |
8 other studies available for labetalol and Birth Weight
| Article | Year |
|---|---|
Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study.
Topics: Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension, Pregnancy-Induced; Infant; Infa | 2022 |
Beta-blocker subtypes and risk of low birth weight in newborns.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Birth Weight; California; Fem | 2018 |
Which beta-blocker in pregnancy-induced hypertension?
Topics: Atenolol; Birth Weight; Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Labetalol; Pre | 1983 |
[Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases].
Topics: Adult; Apgar Score; Birth Weight; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newbor | 1984 |
Heart rate and heart rate variability during sleep in small-for-gestational age newborns.
Topics: Basal Metabolism; Birth Weight; Female; Fetal Growth Retardation; Gestational Age; Heart Rate; Human | 1994 |
Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis.
Topics: Adult; Apgar Score; Birth Weight; Blood Pressure; Drug Administration Schedule; Female; Gestational | 1993 |
Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Fetal Blood; Gestational Age; Humans; Hyperten | 2000 |
Use of labetalol in the treatment of severe hypertension during pregnancy.
Topics: Adolescent; Adult; Amniotic Fluid; Birth Weight; Ethanolamines; Female; Fetal Blood; Humans; Hyperte | 1979 |